Ftse Mib
33.986,90
0,00%
DAX
18.175,21
1,01%
S&P 500
5.180,74
1,03%
NASDAQ
16.349,25
1,19%
Bitcoin
63.432,85
0,42%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Inozyme Pharma Inc (INZY) Inozyme Pharma Inc (INZY) Notizie

Inozyme Pharma Inc

INZY
4,88
0,14 (2,95%)
07 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
03/5/202414:30GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
08/4/202412:30GLOBEInozyme Pharma Announces Positive Topline Data from Ongoing..
06/4/202400:00GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
02/4/202414:30GLOBEInozyme Pharma to Participate at the 23rd Annual Needham..
26/3/202413:30GLOBEInozyme Pharma to Report Topline Data from Ongoing Phase 1/2..
12/3/202413:30GLOBEInozyme Pharma Reports Full Year 2023 Financial Results and..
26/2/202414:30GLOBEInozyme Pharma to Participate in the TD Cowen 44th Annual..
14/2/202414:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202403:06EDGAR2Form SC 13D/A - General statement of acquisition of..
06/2/202414:30GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
05/12/202314:30GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
16/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
09/11/202314:30GLOBEInozyme Pharma to Participate in Upcoming Investor..
07/11/202322:07EDGAR2Form S-3 - Registration statement under Securities Act of..
07/11/202314:34EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202314:31EDGAR2Form 8-K - Current report
07/11/202314:30GLOBEInozyme Pharma Reports Third Quarter 2023 Financial Results..
03/11/202321:15GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
26/10/202314:30GLOBEInozyme Pharma Announces Presentation at the American..
10/10/202314:30GLOBEInozyme Pharma Highlights Inclusion of Generalized Arterial..
06/10/202314:30GLOBEInozyme Pharma Announces Three Poster Presentations at the..
03/10/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202322:12EDGAR2Form 8-K - Current report
26/9/202313:30GLOBEInozyme Pharma Announces Positive Interim Data from Ongoing..
20/9/202314:30GLOBEInozyme Pharma to Host Virtual Investor and Analyst Event on..
06/9/202314:30GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
05/9/202314:30GLOBEInozyme Pharma to Present at the H.C. Wainwright 25th Annual..
11/8/202322:08EDGAR2Form SC 13D/A - General statement of acquisition of..
08/8/202315:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202314:37EDGAR2Form 8-K - Current report
08/8/202314:30GLOBEInozyme Pharma Reports Second Quarter 2023 Financial Results..
08/8/202303:58EDGAR2Form SC 13D/A - General statement of acquisition of..
04/8/202302:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202322:01GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
01/8/202322:01GLOBEInozyme Pharma, Inc. Announces Closing of Public Offering of..
28/7/202323:19EDGAR2Form 8-K - Current report
28/7/202323:17EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/7/202305:20GLOBEInozyme Pharma, Inc. Announces Pricing of Public Offering of..
27/7/202323:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
27/7/202322:33GLOBEInozyme Pharma, Inc. Announces Proposed Offering of Common..
26/7/202313:42EDGAR2Form 8-K - Current report
26/7/202313:30GLOBEInozyme Pharma Announces Updates on Global Development..
19/7/202314:30GLOBEInozyme Pharma to Provide ENPP1 Deficiency Program Update on..
27/6/202314:30GLOBEInozyme Pharma Announces Dosing of First Infant with ENPP1..
02/6/202313:30GLOBEInozyme Pharma to Present at the Jefferies Healthcare..
09/5/202314:30GLOBEInozyme Pharma Reports First Quarter 2023 Financial Results..
Apertura: 4,80 Min: 4,76 Max: 4,90
Chiusura: 4,74

La tua Cronologia

NASDAQ
INZY
Inozyme Pharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network